Chapter PDF
Literatur
Banting FG, Best CH (1922) Pancreatic extracts. J Lab Clin Med 7: 464–472
Berson SA, Yalow RS (1959) Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest 39: 1996
Bertram F (1953) Klinische Beobachtungen über neue verzögernd wirkende Insulinpräparate. Verh Dtsch Ges Inn Med 59: 242
Bolli GB, Owens DR (2000) Insulin glargine. Lancet 356: 443–445
Brange J, Owens DR, Kang S, Solund A (1990) Monomeric insulins and their experimental and clinical implications. Diabetes Care 13: 923–954
Chance RE, Kroeff EP, Hoffmann JA, Frank BH (1981) Chemical, physical and biologic properties of biosynthetic human insulin. Diabetes Care 4: 147–154
Danne T, Deiss D, Hopfenmüller W, von Schütz W, Kordonouri O (2002) Experience with insulin analogues in children. Horm Res 57 (Suppl. 1): 46–53
Danne T, Lüpke K, Walte N, von Schütz W, Gall MA (2003) Insulin detemir is characterized by a consistent pharmacokinetic profile across age groups in children, adolescents and adults with type 1 diabetes. Diabetes Care 26: in press
Field JB (1973) Extraction of insulin by liver. Am Rev Med 24: 309
Goeddel DV, Kleid DG, Bolivar F et al. (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76: 106–110
Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I (1936) Protamine insulinate. JAMA 106: 177–180
Hallas-Møller K, Petersen K, Schlichtkrull J (1952) Crystalline and amorphous insulin-zinc compounds with prolonged action. Science 116: 394–399
Heinemann L, Breuer J, Cebulla D, Wüssel B, Bender R, Heise T (1996) Wirkprofil von Normalinsulin, 25/75-Mischinsulin und NPH-Insulin, hergestellt aus gentechnologischem oder semisynthetischem Humaninsulin. Diabetes und Stoffwechsel 5: 157–163
Heinemann L, Heise T (2001) Klinische Wirkungen und Pharmakodynamik der Insulin-Analoga Lispro, Aspart und Glargin. Dtsch Med Wschr 126: 597–604
Heinemann L, Weyer C, Rave K, Rauhaus M, Stiefelhagen O, Heise T (1997) Comparison of the time action profile of U40-and U100-regular human insulin and rapid-acting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes 105: 131–135
Heinemann L, Woodworth JR (1998) Insulin Lispro; Chapter III: Pharmacokinetics and Metabolism of Insulin Lispro. Drugs of Today 34(Suppl. C): 23–36
International Society for Pediatric and Adolescent Diabetes (ISPAD), International Diabetes Federation World Health Organisation (2000) Consensus guidelines for the management of insulin-dependent (type I) diabetes mellitus (IDDM) in childhood and adolescence. PGF Swift. Publ. Medforum (ed), Zeist, Niederlande. http://www.ispad.org, deutsche Fassung: http://www.disetronic.de/download/ 0701_B_ISPAD.pdf
Johnson IS (1983) Human insulin from recombinant DNA technology. Science 219: 632
Kellerer M, Häring HU (2001) Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clin Endocrinol Diabetes 109: 63–64
Krayenbühl C, Rosenberg T (1946) Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab 1: 60–73
Kriegstein E von (2004) Insulin-Tabelle XII/2003. Diabetes und Stoffwechsel 12: 221–224
Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999–1005
Markussen J, Damgaard U, Jørgensen KH, Rasmussen E, Snel L, Thim L, Voigt HO (1982) Production of human monocomponent insulin. In: Hormone Drugs. Gueriguian IL, Bransome ED, Outschoorn AS (eds) Rockville, MD, U.S. Pharm. Conv., p. 116–126
Obermeier R, Geiger R (1976) A new semisynthesis of human insulin. Hoppe Seylers Z Physiol Chem: 357–759
Schatz H, Bottermann P, von Kriegstein E (2000) Insulin-Tabelle 2000. Deutsche Diabetes-Gesellschaft Bochum
Schlichtkrull J, Brange J, Christiansen AH, Hallund O, Heding LG, Jørgensen KH (1972) Clinical aspects of insulin antigenicity. Diabetes 21(Suppl. 2): 649–656
Schlichtkrull J, Funder J, Munck O (1961) Clinical evaluation of a new insulin preparation. In: 4e Congrès de la Féderation internationale du Diabète, Genève (Demole, ed). Editions Médecine et Hygiène, Genève.1: 303–305
Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K (2002) Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 15: 369–376
Scott DA (1934) Crystalline insulin. Biochem J 28: 1592–1602
Scott DA, Fisher AM (1936) Studies on insulin with protamine. J Pharmacol Exp Ther 58: 78–92
Thim L, Hansen MZ, Norris K et al. (1986) Secretion and processing of insulin precursors in yeast. Proc Natl Acad Sci USA 83: 6766
Vorstand der Deutschen Diabetes-Gesellschaft (1994) Standardisierung der Insulinkonzentration auf 100 E/ml am 01.06.1997 in Deutschland, Frankreich und Italien. Diab Stoffw 3: 445–446
Waldhäusl W, Bratusch-Marrain P, Kruse V, Jensen J, Nowotny P, Vierhapper H (1985) Effect of insulin antibodies on insulin pharmacokinetics and glucose utilization in insulindependent diabetic patients. Diabetes 34: 166
Waldhäusl W, Gasic S, Bratusch-Marrain P, Nowotny P (1983) The 75—g oral glucose tolerance test: effect on splanchnic metabolism of substrates and pancreatic hormone release in healthy man. Diabetologia 25: 489
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
(2005). Insulintherapie. In: Diabetes bei Kindern und Jugendlichen. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-26602-X_8
Download citation
DOI: https://doi.org/10.1007/3-540-26602-X_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21186-0
Online ISBN: 978-3-540-26602-0
eBook Packages: Medicine (German Language)